Pharmaceutical

Ajanta Pharma Ltd reported a strong financial performance for the fourth quarter ended March 31, registering an 18.4 percent year-on-year increase in consolidated net profit to Rs. 266.7 crore. The growth was primarily fueled by robust expansion in its US generics business, a key revenue driver. The company had posted a net profit of Rs. 225.26 crore in the corresponding period last year. Revenue from operations also rose significantly to Rs. 1,421.64 crore from Rs. 1,170.41 crore, underscoring improved market traction and operational efficiency across key geographies.

India’s pharmaceutical sector continues to attract investor attention, and Sun Pharmaceutical Industries Ltd. stands out as a compelling stock within the space. Backed by a diversified portfolio, strong specialty drug pipeline, and expanding global footprint, the company has demonstrated consistent financial discipline. 

Lupin Ltd has reached a settlement agreement worth USD 30 million (approximately Rs 250 crore) through its U.S. subsidiary Lupin Pharmaceuticals Inc with Humana Inc, resolving allegations tied to anti-competitive practices. The dispute was part of a broader, consolidated litigation framework in the United States involving multiple pharmaceutical firms. The settlement allows Lupin to mitigate legal uncertainties and refocus on its core business operations, while avoiding prolonged litigation risks in a complex regulatory environment.

Resolution of a Complex Legal Dispute

Aurobindo Pharma has received final approval from the US Food and Drug Administration to manufacture and market a generic version of glycerol phenylbutyrate oral liquid, a treatment for urea cycle disorders. The product, with a strength of 1.1 gram per ml, is therapeutically equivalent to the branded drug Ravicti. With an estimated market size of USD 50.2 million (approximately Rs 420 crore), the approval marks a strategic addition to Aurobindo’s U.S. portfolio, reinforcing its position in niche and specialty therapeutic segments.

Regulatory Milestone Enhances Product Pipeline

Himachal Pradesh has initiated construction of a Rs 250 crore bulk drug park in Una district, marking a decisive step toward strengthening India’s pharmaceutical manufacturing ecosystem. The project is expected to enhance domestic production of active pharmaceutical ingredients (APIs), reduce import dependence, and generate substantial employment opportunities. Positioned as a strategic industrial investment, the park aims to attract leading pharmaceutical companies through upcoming partnerships and agreements.

Himachal Pradesh has initiated work on a Rs 250 crore bulk drug park in Una district, marking a significant step toward strengthening India’s pharmaceutical manufacturing capabilities. The project is expected to enhance the state’s position as a key hub for drug production while generating substantial employment opportunities. Positioned as a project of national importance, the initiative aligns with India’s broader objective of reducing dependency on imports and building a resilient domestic supply chain.

India’s healthcare and pharmaceutical industry is entering a new phase of capability-driven expansion, with projections indicating the creation of 2 to 2.5 million jobs by 2030. However, this growth comes with a structural shift, as nearly 30 to 35 per cent of the workforce will require reskilling to meet evolving industry demands. The transformation is being driven by technological integration, rising specialization, and expansion across segments such as telemedicine, diagnostics, and life sciences.

India’s pharmaceutical sector is being urged to reduce its reliance on imported raw materials and strengthen domestic manufacturing capabilities amid rising global uncertainties. A senior government official emphasized the need to achieve 80–90 per cent self-sufficiency in critical inputs such as APIs and bulk drugs while expanding export markets. Despite India’s presence in nearly 200 countries, significant opportunities remain to diversify supply chains and enhance resilience.

Lupin Ltd has received tentative approval from the US Food and Drug Administration for its generic version of Pitolisant tablets, used to treat excessive daytime sleepiness. The approval, granted under the abbreviated new drug application (ANDA) pathway, covers strengths of 4.45 mg and 17.8 mg. The product will be manufactured at Lupin’s Nagpur facility, reinforcing its global manufacturing footprint. This development highlights Lupin’s continued focus on expanding its central nervous system (CNS) portfolio while strengthening its presence in the highly regulated US generics market.

CureBay has acquired the pharmacy distribution business of Saveo Healthtech, strengthening its position in India’s healthcare delivery ecosystem. The acquired business operates a technology-driven B2B pharmaceutical supply network, serving more than 10,000 retail pharmacies across southern India. This strategic move enhances CureBay’s ability to ensure consistent and affordable medicine access, particularly in underserved regions.